FDA committee backs GSK's multiple myeloma drug

15th July 2020 Uncategorised 0

If approved, belantamab mafodotin will be a first-in-class anti-BCMA therapy for relapsed/refractory multiple myeloma

More: FDA committee backs GSK's multiple myeloma drug
Source: News